# KZR-261 in Subjects With Advanced Solid Malignancies

> **NCT05047536** · PHASE1 · TERMINATED · sponsor: **Kezar Life Sciences, Inc.** · enrollment: 61 (actual)

## Conditions studied

- Advanced/Metastatic Solid Tumor

## Interventions

- **DRUG:** KZR-261

## Key facts

- **NCT ID:** NCT05047536
- **Lead sponsor:** Kezar Life Sciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-30
- **Primary completion:** 2025-01-17
- **Final completion:** 2025-01-17
- **Target enrollment:** 61 (ACTUAL)
- **Why stopped:** Sponsor decision.
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05047536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05047536, "KZR-261 in Subjects With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05047536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*